Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial
Journal of Clinical Oncology · 01.01.2024 · 42 (1) · 13-18
DOI: 10.1200/jco.23.01177 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.01.2024. Verfasst von Stefano Luminari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Azienda USL IRCCS of Reggio Emilia, Reggio Emilia, Italy. Hauptthemen laut MEDLINE: Hodgkin Disease, Neoplasms, Second Primary. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, Cancer Research UK.
Abstract (Originalsprache)
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We analyzed long-term results of the response-adapted trial for adult patients with advanced-stage Hodgkin lymphoma. The aim was to confirm noninferiority of treatment de-escalation by omission of bleomycin from doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for interim fluorodeoxyglucose positron emission tomography (iPET)–negative patients and assess efficacy and long-term safety for iPET-positive patients who underwent treatment intensification with escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone (BEACOPP/BEACOPP14). The median follow-up is 7.3 years. For all patients, the 7-year progression-free survival (PFS) and overall survival (OS) are 78.2% (95% CI, 75.6 to 80.5) and 91.6% (95% CI, 89.7 to 93.2), respectively. The 1.3% difference in 3-year PFS (95% CI, –3.0 to 4.7) between ABVD and doxorubicin, vinblastine, and dacarbazine (AVD) now falls within the predefined noninferiority margin. Among 172 patients with positive iPET, the 7-year PFS was 65.9% (95% CI, 58.1 to 72.6) and the 7-year OS was 83.2% (95% CI, 76.2 to 88.3). The cumulative incidence of second malignancies at 7 years was 5.5% (95% CI, 4.0 to 7.5) for those receiving ABVD/AVD and 2.5% (95% CI, 0.8 to 7.7) for those escalated to BEACOPP. With extended follow-up, these results confirm noninferiority of treatment de-escalation after a negative iPET. Escalation with BEACOPP for iPET-positive patients is effective and safe, with no increase in second malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hematology, Azienda USL IRCCS of Reggio Emilia, Reggio Emilia, Italy.
- Department CHIMOMO, University of Modena and Reggio Emilia, Modena, Italy.
- Department of Medical Oncology, Oslo University Hospital, Oslo, Norway.
- Concord Repatriation General Hospital, University of Sydney, Sydney, Australia.
- Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden.
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
ORCID-Profile: Stefano Luminari, Judith Trotman, Francesco d'Amore, Gunilla Enblad, Sally F Barrington, John Radford, Massimo Federico, Peter W M Johnson
Förderung
- Wellcome Trust
- Cancer Research UK
Zitieren
APA
Luminari, S., Fossa, A., Trotman, J., Molin, D., d'Amore, F., Enblad, G., Berkahn, L., Barrington, S. F., Radford, J., Federico, M., Kirkwood, A. A., & Johnson, P. W. M. (2024). Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. Journal of Clinical Oncology, 42(1), 13-18. https://doi.org/10.1200/jco.23.01177
Vancouver
Luminari S, Fossa A, Trotman J, Molin D, d'Amore F, Enblad G, et al. Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. Journal of Clinical Oncology. 2024;42(1):13-18. doi:10.1200/jco.23.01177
BibTeX
@article{Luminari2024,
author = {Luminari, Stefano and Fossa, Alexander and Trotman, Judith and Molin, Daniel and d'Amore, Francesco and Enblad, Gunilla and Berkahn, Leanne and Barrington, Sally F and Radford, John and Federico, Massimo and Kirkwood, Amy A and Johnson, Peter W M},
title = {Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {1},
pages = {13--18},
doi = {10.1200/jco.23.01177}
}
EUVIMED